Embodiments of the subject matter described herein relate generally to fluid infusion devices for delivering a medication fluid to the body of a user. More particularly, embodiments of the subject matter relate to the use of a trapping chamber in the medication fluid flow path.
Certain diseases or conditions may be treated, according to modern medical techniques, by delivering a medication fluid or other substance to the body of a patient, either in a continuous manner or at particular times or time intervals within an overall time period. For example, diabetes is commonly treated by delivering defined amounts of insulin to the patient at appropriate times. Some common modes of providing insulin therapy to a patient include delivery of insulin through manually operated syringes and insulin pens. Other modern systems employ programmable fluid infusion devices (e.g., continuous insulin infusion devices such as insulin pumps) to deliver controlled amounts of insulin or other drugs to a patient.
A fluid infusion device suitable for use as an insulin pump may be realized as an external device or an implantable device, which is surgically implanted into the body of the patient. External fluid infusion devices include devices designed for use in a generally stationary location (for example, in a hospital or clinic), and devices configured for ambulatory or portable use (to be carried by a patient). External fluid infusion devices may establish a fluid flow path from a fluid reservoir to the patient via, for example, a suitable hollow tubing. The hollow tubing may be connected to a hollow fluid delivery needle that is designed to pierce the patient's skin to deliver an infusion fluid to the body. Alternatively, the hollow tubing may be connected directly to the patient's body through a cannula or set of micro-needles.
It is desirable to reduce the amount of air bubbles in a medication fluid before delivering the fluid to the patient. Small bubbles may be introduced into the medication fluid during a reservoir filling operation, for example, when the fluid reservoir is filled from a vial using a syringe. Bubbles can also be generated during temperature or altitude changes. Although patients are instructed to eliminate air from a filled reservoir, some micro bubbles may remain.
Accordingly, it is desirable to have an assembly, system, or component that is designed to mitigate the effects of air bubbles within a medication fluid flow path. Furthermore, other desirable features and characteristics will become apparent from the subsequent detailed description and the appended claims, taken in conjunction with the accompanying drawings and the foregoing technical field and background.
Disclosed herein is a fluid conduit assembly for delivery of a medication fluid. An exemplary embodiment of the fluid conduit assembly includes a trapping chamber having an interior volume to receive the medication fluid. The fluid conduit assembly also includes an inlet in fluid communication with the interior volume, a first outlet arrangement for the trapping chamber, and a second outlet arrangement for the trapping chamber. The first outlet arrangement accommodates flow of liquid from the interior volume and inhibits flow of gas from the interior volume. The second outlet arrangement accommodates flow of gas from the interior volume and inhibits flow of liquid from the interior volume.
Yet another embodiment of a fluid conduit assembly presented here includes a trapping chamber having an interior volume to receive fluid, an inlet in fluid communication with the interior volume, a delivery hole formed in a wall of the trapping chamber, a first membrane covering the delivery hole, a vent hole, and a second membrane covering the vent hole. The first membrane has hydrophilic properties to accommodate flow of liquid from the interior volume through the delivery hole while inhibiting flow of gas from the interior volume through the delivery hole. The second membrane has hydrophobic properties to accommodate flow of gas from the interior volume through the vent hole while inhibiting flow of liquid from the interior volume through the vent hole.
Another embodiment of a fluid delivery system is also presented here. The system includes a fluid infusion pump and a fluid conduit assembly coupled to the fluid infusion pump. The fluid conduit assembly includes a trapping chamber having an interior volume to receive fluid from a fluid source, a liquid outlet arrangement, and a gas outlet arrangement. The liquid outlet arrangement allows liquid to flow from the interior volume to a fluid delivery conduit while inhibiting flow of gas from the interior volume to the fluid delivery conduit. The gas outlet arrangement allows gas to exit the interior volume while inhibiting flow of liquid from the interior volume.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures.
The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
The subject matter described here relates to certain assemblies, components, and features of a fluid infusion system of the type used to treat a medical condition of a patient. The fluid infusion system is used for infusing a medication fluid into the body of a user. The non-limiting examples described below relate to a medical device used to treat diabetes (more specifically, an insulin pump), although embodiments of the disclosed subject matter are not so limited. Accordingly, the medication fluid is insulin in certain embodiments. In alternative embodiments, however, many other fluids may be administered through infusion such as, but not limited to, disease treatments, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like. Moreover, the gas trapping filter described below could be utilized in the context of other fluid delivery systems if so desired.
For the sake of brevity, conventional features and technologies related to infusion system operation, insulin pump and/or infusion set operation, and other functional aspects of the fluid infusion system (and the individual operating components of the system) may not be described in detail here. Examples of infusion pumps and/or related pump drive systems used to administer insulin and other medications may be of the type described in, but not limited to, U.S. Pat. Nos. 4,562,751; 4,678,408; 4,685,903; 5,080,653; 5,505,709; 5,097,122; 6,485,465; 6,554,798; 6,558,351; 6,659,980; 6,752,787; 6,817,990; 6,932,584; and 7,621,893; which are herein incorporated by reference.
The fluid infusion device 102 may be provided in any desired configuration or platform. In accordance with one non-limiting embodiment, the fluid infusion device is realized as a portable unit that can be carried or worn by the patient. In this regard,
The illustrated embodiment of the infusion set component 204 includes, without limitation: a tube 210; an infusion unit 212 coupled to the distal end of the tube 210; and a connector assembly 214 coupled to the proximal end of the tube 210. The fluid infusion device 202 is designed to be carried or worn by the patient, and the infusion set component 204 terminates at the infusion unit 212 such that the fluid infusion device 202 can deliver fluid to the body of the patient via the tube 210. The fluid infusion device 202 may leverage a number of conventional features, components, elements, and characteristics of existing fluid infusion devices. For example, the fluid infusion device 202 may incorporate some of the features, components, elements, and/or characteristics described in U.S. Pat. Nos. 6,485,465 and 7,621,893, the relevant content of which is incorporated by reference herein.
The infusion set component 204 defines a fluid flow path that fluidly couples the fluid reservoir to the infusion unit 212. The connector assembly 214 mates with and couples to the neck region of the fluid reservoir, establishing the fluid path from the fluid reservoir to the tube 210. The connector assembly 214 (with the fluid reservoir coupled thereto) is coupled to the housing of the fluid infusion device 202 to seal and secure the fluid reservoir inside the housing. Thereafter, actuation of the fluid infusion device 202 causes the medication fluid to be expelled from the fluid reservoir, through the infusion set component 204, and into the body of the patient via the infusion unit 212 at the distal end of the tube 210. Accordingly, when the connector assembly 214 is installed as depicted in
The base plate 306 is designed to be temporarily adhered to the skin of the patient using, for example, an adhesive layer of material. After the base plate is affixed to the skin of the patient, a suitably configured insertion device or apparatus may be used to insert a fluid delivery needle or cannula 308 into the body of the patient. The cannula 308 functions as one part of the fluid delivery flow path associated with the fluid infusion device 302. In this regard, the cannula 308 and/or other structure in fluid communication with the cannula 308 may be considered to be one implementation of the fluid conduit assembly 104 shown in
The fluid delivery systems 200, 300 described here are merely two exemplary embodiments that can include a fluid conduit assembly outfitted with a trapping chamber of the type described in more detail below. More specifically, the fluid delivery systems 200, 300 can manage the presence of gas/air in the medication fluid by way of a gas-venting trapping chamber, which can be incorporated into a fluid conduit assembly of the fluid delivery system. In this regard,
Ideally, medication fluid that enters the trapping chamber 400 should be free of bubbles, air, and other gas components. In practice, however, the liquid component of the medication fluid may contain some micro bubbles or trace amounts of gas. The trapping chamber 400 serves as a “staging area” for the received fluid during a fluid delivery operation. The trapping chamber 400 includes or cooperates with a liquid outlet arrangement 406 that facilitates flow of liquid out of the trapping chamber 400, and a gas outlet arrangement 408 that facilitates flow of gas out of the trapping chamber 400. More specifically, the liquid outlet arrangement 406 is suitably configured to accommodate flow of liquid from the interior volume 402 while inhibiting flow of gas from the interior volume 402. Conversely, the gas outlet arrangement 408 is suitably configured to accommodate flow of gas from the interior volume 402 while inhibiting flow of liquid from the interior volume 402. Although not depicted in
The trapping chamber 400 that is schematically depicted in
The illustrated embodiment of the reservoir cap 500 generally includes, without limitation: a body section 502; a flow path defined in the body section; a length of tubing 504 extending from the body section 502; and a trapping chamber (hidden from view).
The lower body section 502b is suitably configured to receive a fluid reservoir, e.g., by a threaded engagement, a snap fit, tabs, or the like. The tubing 504 is physically and fluidly coupled to the upper body section 502b such that the tubing 504 is in fluid communication with the flow path. This allows the tubing 504 to carry fluid from the body section 502 during a fluid delivery operation. The flow path, much of which is hidden from view in
The trapping chamber resides within the body section 502 such that it is positioned in the flow path of the medication fluid. During a fluid delivery operation, the medication fluid is forced out of the fluid reservoir and into the hollow needle (not shown in
The exemplary embodiment of the fluid conduit assembly 900 generally includes, without limitation: the trapping chamber 902; an inlet 904 in fluid communication with an interior volume 906 of the trapping chamber 902; a hollow needle 908 coupled to the inlet 904; a liquid outlet arrangement 910 for the trapping chamber 902; a gas outlet arrangement 912 for the trapping chamber 902; and a length of hollow tubing 914 that serves as a fluid delivery conduit. During a fluid delivery operation, such as an insulin delivery operation of an insulin infusion pump, the desired fluid (e.g., insulin medication fluid) is dispensed from a fluid source such as a fluid reservoir. The hollow needle 908 is compatible with the fluid delivery source and the host fluid infusion system. The dispensed fluid enters the interior volume 906 by way of the hollow needle 908, which is in fluid communication with the fluid source. The liquid outlet arrangement 910 allows liquid to flow from the interior volume 906 to the hollow tubing 914, while inhibiting or preventing the flow of gas from the interior volume 906 to the hollow tubing 914. The gas outlet arrangement 912 allows gas to exit the interior volume 906, while inhibiting or preventing the flow of liquid from the interior volume 906.
The illustrated embodiment of the liquid outlet arrangement 910 includes, without limitation: at least one delivery hole 920 formed in a wall 922 of the trapping chamber 902; and at least one membrane 924 (also referred to here as the first membrane 924) covering or blocking at least a portion of the at least one delivery hole 920. For simplicity,
The first membrane 924 exhibits hydrophilic properties, such that liquid can easily pass through the first membrane 924. Moreover, the properties of the first membrane 924 inhibit or prevent the flow of gas through the first membrane 924. Thus, the first membrane 924 is fabricated from a material (or materials) that is partially or predominantly hydrophilic. The hydrophilic characteristic of the first membrane 924 facilitates the flow of liquid medication fluid from the interior volume 906 to the hollow tubing 914, which is in fluid communication with the liquid outlet arrangement 910.
The first membrane 924 is formed from a suitable material, composition, or element such that the medication fluid can easily pass through the first membrane during fluid delivery operations. The first membrane 924 can be formed from a hydrophilic, semi-hydrophilic, partially hydrophilic, or predominantly hydrophilic material. Although a truly hydrophilic material may be ideal, the material used for the first membrane 924 can be partially or predominantly hydrophilic while exhibiting some amount of hydrophobicity. Non-limiting examples of suitable materials for the first membrane 924 include: polyacrylate; polyurethane; nylon; cellulose acetate; polyvinyl alcohol; polyethelene foam; polyvinyl acetate; polyester fiber felt; polyester (PET); polysulfone; polyethyl sulfone; collagen; polycaprolactone; or the like. It should be appreciated that the material or materials used to fabricate the first membrane 924 can be treated to enhance the hydrophilic characteristics if so desired.
The illustrated embodiment of the gas outlet arrangement 912 includes, without limitation: at least one vent hole 930 formed in the wall 922 of the trapping chamber 902; and at least one membrane 934 (also referred to here as the second membrane 934) covering or blocking at least a portion of the at least one vent hole 930. The cross-sectional view of
The second membrane 934 exhibits hydrophobic properties, such that gas can easily pass through the second membrane 934. Moreover, the properties of the second membrane 934 inhibit or prevent the flow of liquid through the second membrane 934. Thus, the second membrane 934 is fabricated from a material (or materials) that is partially or predominantly hydrophobic. Indeed, the second membrane 934 can be fabricated using any suitable material or composition, including, without limitation: polytetrafluoroethylene (PTFE); fluoropolymers; glass fiber; treated or coated materials; or the like. The hydrophobic characteristic of the second membrane 934 facilitates the venting of gas/air from the interior volume 906 of the trapping chamber 902. In this regard, the vent holes 930 are preferably arranged and configured to exit into external airspace surrounding the trapping chamber 902. In other words, the vent holes 930 terminate at a location that is at ambient temperature and pressure.
In certain embodiments where the trapping chamber 902 is integrated into a reservoir cap of the type utilized with an insulin infusion pump, the hollow needle 908 receives insulin during a delivery operation that advances a piston or plunger of an insulin reservoir. In such an implementation, the interior volume 906 of the trapping chamber 902 can be within the range of about 1.0 microliters to about 500 microliters, although the actual volume may fall outside of this range in some embodiments. During a typical insulin delivery operation, the pressure within the interior volume 906 of the trapping chamber 902 can be within the range of about 1.0 psi to about 30 psi, although the actual pressure may fall outside of this range in some embodiments. The fluid pressure inside the trapping chamber 902 is sufficient to force the liquid insulin through the first membrane 924, and is sufficient to vent air or other gas components through the second membrane 934 as needed.
The illustrated embodiment includes four vent holes 930 formed in a circular pattern around the delivery hole 920. It should be appreciated that other venting configurations and arrangements can be utilized in lieu of that shown in
As explained above, a trapping chamber can be incorporated into a reservoir cap of an infusion pump. Referring to
In addition to the trapping chamber and venting arrangement described above, a reservoir cap may also include pressure vent holes formed therein for purposes of equalizing pressure inside the reservoir chamber. In certain embodiments, the pressure vent holes are formed in the wall 922 depicted in
Notably, the hydrophobic membrane 934 (see
While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application.
Number | Name | Date | Kind |
---|---|---|---|
3631847 | Hobbs, II | Jan 1972 | A |
3803810 | Rosenberg | Apr 1974 | A |
4009715 | Forberg | Mar 1977 | A |
4190426 | Ruschke | Feb 1980 | A |
4200095 | Reti | Apr 1980 | A |
4212738 | Henne | Jul 1980 | A |
4270532 | Franetzki et al. | Jun 1981 | A |
4282872 | Franetzki et al. | Aug 1981 | A |
4373527 | Fischell | Feb 1983 | A |
4395259 | Prestele et al. | Jul 1983 | A |
4433072 | Pusineri et al. | Feb 1984 | A |
4443218 | DeCant, Jr. et al. | Apr 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4542532 | McQuilkin | Sep 1985 | A |
4550731 | Batina et al. | Nov 1985 | A |
4559037 | Franetzki et al. | Dec 1985 | A |
4562751 | Nason et al. | Jan 1986 | A |
4642098 | Lundquist | Feb 1987 | A |
4671288 | Gough | Jun 1987 | A |
4678408 | Nason et al. | Jul 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4731051 | Fischell | Mar 1988 | A |
4731726 | Allen, III | Mar 1988 | A |
4781798 | Gough | Nov 1988 | A |
4803625 | Fu et al. | Feb 1989 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4826810 | Aoki | May 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
5003298 | Havel | Mar 1991 | A |
5011468 | Lundquist et al. | Apr 1991 | A |
5019974 | Beckers | May 1991 | A |
5050612 | Matsumura | Sep 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5080653 | Voss et al. | Jan 1992 | A |
5097122 | Colman et al. | Mar 1992 | A |
5100380 | Epstein et al. | Mar 1992 | A |
5101814 | Palti | Apr 1992 | A |
5108819 | Heller et al. | Apr 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5165407 | Wilson et al. | Nov 1992 | A |
5247434 | Peterson et al. | Sep 1993 | A |
5262035 | Gregg et al. | Nov 1993 | A |
5262305 | Heller et al. | Nov 1993 | A |
5264104 | Gregg et al. | Nov 1993 | A |
5264105 | Gregg et al. | Nov 1993 | A |
5284140 | Allen et al. | Feb 1994 | A |
5299571 | Mastrototaro | Apr 1994 | A |
5307263 | Brown | Apr 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5320725 | Gregg et al. | Jun 1994 | A |
5322063 | Allen et al. | Jun 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5339821 | Fujimoto | Aug 1994 | A |
5341291 | Roizen et al. | Aug 1994 | A |
5350411 | Ryan et al. | Sep 1994 | A |
5356786 | Heller et al. | Oct 1994 | A |
5357427 | Langen et al. | Oct 1994 | A |
5362406 | Gsell | Nov 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5370622 | Livingston et al. | Dec 1994 | A |
5371687 | Holmes, II et al. | Dec 1994 | A |
5376070 | Purvis et al. | Dec 1994 | A |
5390671 | Lord et al. | Feb 1995 | A |
5391250 | Cheney, II et al. | Feb 1995 | A |
5403700 | Heller et al. | Apr 1995 | A |
5411647 | Johnson et al. | May 1995 | A |
5439587 | Stankowski | Aug 1995 | A |
5482473 | Lord et al. | Jan 1996 | A |
5485408 | Blomquist | Jan 1996 | A |
5497772 | Schulman et al. | Mar 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5522769 | DeGuiseppi | Jun 1996 | A |
5543326 | Heller et al. | Aug 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5569187 | Kaiser | Oct 1996 | A |
5573506 | Vasko | Nov 1996 | A |
5575279 | Beplate | Nov 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5586553 | Halili et al. | Dec 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5593852 | Heller et al. | Jan 1997 | A |
5594638 | Iliff | Jan 1997 | A |
5609060 | Dent | Mar 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5643212 | Coutre et al. | Jul 1997 | A |
5660163 | Schulman et al. | Aug 1997 | A |
5660176 | Iliff | Aug 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5665222 | Heller et al. | Sep 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5687734 | Dempsey et al. | Nov 1997 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5750926 | Schulman et al. | May 1998 | A |
5754111 | Garcia | May 1998 | A |
5764159 | Neftel | Jun 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5779665 | Mastrototaro et al. | Jul 1998 | A |
5788669 | Peterson | Aug 1998 | A |
5791344 | Schulman et al. | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807336 | Russo et al. | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5832448 | Brown | Nov 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5861018 | Feierbach et al. | Jan 1999 | A |
5868669 | Iliff | Feb 1999 | A |
5871465 | Vasko | Feb 1999 | A |
5879163 | Brown et al. | Mar 1999 | A |
5885245 | Lynch et al. | Mar 1999 | A |
5897493 | Brown | Apr 1999 | A |
5899855 | Brown | May 1999 | A |
5904708 | Goedeke | May 1999 | A |
5913310 | Brown | Jun 1999 | A |
5917346 | Gord | Jun 1999 | A |
5918603 | Brown | Jul 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5933136 | Brown | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5940801 | Brown | Aug 1999 | A |
5956501 | Brown | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5965380 | Heller et al. | Oct 1999 | A |
5972199 | Heller et al. | Oct 1999 | A |
5978236 | Faberman et al. | Nov 1999 | A |
5997476 | Brown | Dec 1999 | A |
5999848 | Gord et al. | Dec 1999 | A |
5999849 | Gord et al. | Dec 1999 | A |
6009339 | Bentsen et al. | Dec 1999 | A |
6032119 | Brown et al. | Feb 2000 | A |
6043437 | Schulman et al. | Mar 2000 | A |
6081736 | Colvin et al. | Jun 2000 | A |
6083710 | Heller et al. | Jul 2000 | A |
6088608 | Schulman et al. | Jul 2000 | A |
6101478 | Brown | Aug 2000 | A |
6103033 | Say et al. | Aug 2000 | A |
6119028 | Schulman et al. | Sep 2000 | A |
6120676 | Heller et al. | Sep 2000 | A |
6121009 | Heller et al. | Sep 2000 | A |
6134461 | Say et al. | Oct 2000 | A |
6143164 | Heller et al. | Nov 2000 | A |
6162611 | Heller et al. | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6183412 | Benkowski et al. | Feb 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6259937 | Schulman et al. | Jul 2001 | B1 |
6329161 | Heller et al. | Dec 2001 | B1 |
6408330 | DeLaHuerga | Jun 2002 | B1 |
6424847 | Mastrototaro et al. | Jul 2002 | B1 |
6472122 | Schulman et al. | Oct 2002 | B1 |
6484045 | Holker et al. | Nov 2002 | B1 |
6484046 | Say et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6503381 | Gotoh et al. | Jan 2003 | B1 |
6514718 | Heller et al. | Feb 2003 | B2 |
6544173 | West et al. | Apr 2003 | B2 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6560741 | Gerety et al. | May 2003 | B1 |
6565509 | Say et al. | May 2003 | B1 |
6579690 | Bonnecaze et al. | Jun 2003 | B1 |
6585695 | Adair | Jul 2003 | B1 |
6591125 | Buse et al. | Jul 2003 | B1 |
6592745 | Feldman et al. | Jul 2003 | B1 |
6605200 | Mao et al. | Aug 2003 | B1 |
6605201 | Mao et al. | Aug 2003 | B1 |
6607658 | Heller et al. | Aug 2003 | B1 |
6616819 | Liamos et al. | Sep 2003 | B1 |
6618934 | Feldman et al. | Sep 2003 | B1 |
6623501 | Heller et al. | Sep 2003 | B2 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6654625 | Say et al. | Nov 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6671554 | Gibson et al. | Dec 2003 | B2 |
6676816 | Mao et al. | Jan 2004 | B2 |
6689265 | Heller et al. | Feb 2004 | B2 |
6728576 | Thompson et al. | Apr 2004 | B2 |
6733471 | Ericson et al. | May 2004 | B1 |
6746582 | Heller et al. | Jun 2004 | B2 |
6747556 | Medema et al. | Jun 2004 | B2 |
6749740 | Liamos et al. | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6809653 | Mann et al. | Oct 2004 | B1 |
6817990 | Yap et al. | Nov 2004 | B2 |
6881551 | Heller et al. | Apr 2005 | B2 |
6892085 | McIvor et al. | May 2005 | B2 |
6893545 | Gotoh et al. | May 2005 | B2 |
6895263 | Shin et al. | May 2005 | B2 |
6916159 | Rush et al. | Jul 2005 | B2 |
6932584 | Gray et al. | Aug 2005 | B2 |
6932894 | Mao et al. | Aug 2005 | B2 |
6942518 | Liamos et al. | Sep 2005 | B2 |
7153263 | Carter et al. | Dec 2006 | B2 |
7153289 | Vasko | Dec 2006 | B2 |
7396330 | Banet et al. | Jul 2008 | B2 |
7621893 | Moberg et al. | Nov 2009 | B2 |
20010044731 | Coffman et al. | Nov 2001 | A1 |
20020013518 | West et al. | Jan 2002 | A1 |
20020055857 | Mault et al. | May 2002 | A1 |
20020077598 | Yap et al. | Jun 2002 | A1 |
20020082665 | Haller et al. | Jun 2002 | A1 |
20020137997 | Mastrototaro et al. | Sep 2002 | A1 |
20020161288 | Shin et al. | Oct 2002 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030078560 | Miller et al. | Apr 2003 | A1 |
20030088166 | Say et al. | May 2003 | A1 |
20030144581 | Conn et al. | Jul 2003 | A1 |
20030152823 | Heller | Aug 2003 | A1 |
20030176183 | Drucker et al. | Sep 2003 | A1 |
20030188427 | Say et al. | Oct 2003 | A1 |
20030199744 | Buse et al. | Oct 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030220552 | Reghabi et al. | Nov 2003 | A1 |
20040061232 | Shah et al. | Apr 2004 | A1 |
20040061234 | Shah et al. | Apr 2004 | A1 |
20040064133 | Miller et al. | Apr 2004 | A1 |
20040064156 | Shah et al. | Apr 2004 | A1 |
20040073095 | Causey, III et al. | Apr 2004 | A1 |
20040074785 | Holker et al. | Apr 2004 | A1 |
20040093167 | Braig et al. | May 2004 | A1 |
20040097796 | Berman et al. | May 2004 | A1 |
20040102683 | Khanuja et al. | May 2004 | A1 |
20040111017 | Say et al. | Jun 2004 | A1 |
20040122353 | Shahmirian et al. | Jun 2004 | A1 |
20040167465 | Mihai et al. | Aug 2004 | A1 |
20040263354 | Mann et al. | Dec 2004 | A1 |
20050038331 | Silaski et al. | Feb 2005 | A1 |
20050038680 | McMahon et al. | Feb 2005 | A1 |
20050154271 | Rasdal et al. | Jul 2005 | A1 |
20050192557 | Brauker et al. | Sep 2005 | A1 |
20060229694 | Schulman et al. | Oct 2006 | A1 |
20060238333 | Welch et al. | Oct 2006 | A1 |
20060293571 | Bao et al. | Dec 2006 | A1 |
20070088521 | Shmueli et al. | Apr 2007 | A1 |
20070135866 | Baker et al. | Jun 2007 | A1 |
20080154503 | Wittenber et al. | Jun 2008 | A1 |
20090081951 | Erdmann et al. | Mar 2009 | A1 |
20090082635 | Baldus et al. | Mar 2009 | A1 |
20120172800 | Dudar et al. | Jul 2012 | A1 |
20130103002 | Fruenlund | Apr 2013 | A1 |
Number | Date | Country |
---|---|---|
4329229 | Mar 1995 | DE |
0057001 | Aug 1982 | EP |
0319268 | Nov 1988 | EP |
0806738 | Nov 1997 | EP |
0880936 | Dec 1998 | EP |
1338295 | Aug 2003 | EP |
1442761 | Aug 2004 | EP |
1631036 | Mar 2006 | EP |
2500051 | Sep 2012 | EP |
1401382 | Jul 1975 | GB |
2218831 | Nov 1989 | GB |
WO 9506506 | Mar 1995 | WO |
WO 9506506 | Mar 1995 | WO |
WO 9620745 | Jul 1996 | WO |
WO 9636389 | Nov 1996 | WO |
WO 9637246 | Nov 1996 | WO |
WO 9721456 | Jun 1997 | WO |
WO 9820439 | May 1998 | WO |
WO 9824358 | Jun 1998 | WO |
WO 9842407 | Oct 1998 | WO |
WO 9849659 | Nov 1998 | WO |
WO 9859487 | Dec 1998 | WO |
WO 9908183 | Feb 1999 | WO |
WO 9910801 | Mar 1999 | WO |
WO 9918532 | Apr 1999 | WO |
WO 9922236 | May 1999 | WO |
WO 0010628 | Mar 2000 | WO |
WO 0019887 | Apr 2000 | WO |
WO 0048112 | Aug 2000 | WO |
WO 02058537 | Aug 2002 | WO |
WO 03001329 | Jan 2003 | WO |
WO 03094090 | Nov 2003 | WO |
WO 2005065538 | Jul 2005 | WO |
Entry |
---|
PCT Search Report (PCT/US02/03299), dated Oct. 31, 2002, Medtronic Minimed, Inc. |
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy. |
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327. |
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition. |
Brackenridge B P (1992). Carbohydrate Gram Counting a Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28. |
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc. |
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138. |
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283. |
Kulkarni K et al. (1999). Carbohydrate Counting a Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc. |
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142. |
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38. |
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company. |
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed•Technologies. |
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60. |
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed•Technologies. |
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78. |
Disetronic My Choice™ D-TRON™ Insulin Pump Reference Manual. (no date). |
Disetronic H-TRON® plus Quick Start Manual. (no date). |
Disetronic My Choice H-TRONplus Insulin Pump Reference Manual. (no date). |
Disetronic H-TRON®plus Reference Manual. (no date). |
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506—pic.htm. |
(MiniMed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm. |
(MiniMed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq—pract.htm. |
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm. |
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide. |
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines / MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages. |
(MiniMed, 1996). MiniMed™ 507 Insulin Pump User's Guide. |
(MiniMed, 1997). MiniMed™ 507 Insulin Pump User's Guide. |
(MiniMed, 1998). MiniMed 507C Insulin Pump User's Guide. |
(MiniMed International, 1998). MiniMed 507C Insulin Pump for those who appreciate the difference. |
(MiniMed Inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy. |
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life. |
(MiniMed, 2000). MiniMed® 508 User's Guide. |
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management. |
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence. |
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version. |
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584. |
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696. |
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197. |
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473. |
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540. |
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70. |
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241. |
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analytica Chimica Acta, 249, 1991, pp. 43-54. |
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357. |
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, 62, pp. 258-263. |
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975. |
Hashiguchi, Yasuhiro, MD, et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389. |
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134. |
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179. |
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714. |
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468. |
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Linearity,” Sensors and Actuators, B. 10, 1992, pp. 37-40. |
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765. |
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52. |
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36. |
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165. |
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144. |
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991. |
McKean, Brian D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532. |
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16. |
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484. |
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077. |
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172. |
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358. |
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine-co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103. |
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663. |
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220. |
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406. |
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only for a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9. |
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292. |
Shichiri, Motoaki, et al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202. |
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184. |
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20. |
Shichiri, M., et al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313. |
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275. |
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301. |
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131. |
Shichiri, Motoaki, et al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370. |
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041. |
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942. |
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40. |
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators, vol. 18, 1989, pp. 297-307. |
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091. |
Urban, G., et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739. |
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562. |
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233. |
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847. |
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98. |
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytica Chimica Acta, vol. 218, 1989, pp. 137-142. |
Number | Date | Country | |
---|---|---|---|
20160144102 A1 | May 2016 | US |